The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.
 
Daniel B Landi
No Relationships to Disclose
 
David S. Ziegler
Consulting or Advisory Role - Accendatech; Amgen; AstraZeneca/Merck; Bayer; Day One Biopharmaceuticals; FivePhusion; Novartis
Research Funding - Accendatech (Inst)
Travel, Accommodations, Expenses - Bayer
 
Andrea Flynn Franson
No Relationships to Disclose
 
Patricia Ann Baxter
No Relationships to Disclose
 
Sarah Leary
Research Funding - Blaze Bioscience (Inst)
 
Valérie Larouche
No Relationships to Disclose
 
Angela Jae Waanders
No Relationships to Disclose
 
Jasper Van der Lugt
No Relationships to Disclose
 
Geoffrey Brian McCowage
Consulting or Advisory Role - Biogen (I)
Research Funding - Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - BIOGEN (I)
 
Francois Doz
No Relationships to Disclose
 
Nada Jabado
No Relationships to Disclose
 
Elisabetta Schiavello
No Relationships to Disclose
 
Michal Zapotocky
No Relationships to Disclose
 
Izzy Cornelio
Employment - Day One Biopharmaceuticals
 
Samuel C Blackman
Employment - Day One Biopharmaceuticals
 
Daniel Da Costa
Employment - Day One Biopharmaceuticals
 
Michael Craig Cox
Employment - Amgen; Bayer; Day One Biopharmaceuticals; Loxo; Merck KGaA
Stock and Other Ownership Interests - Amgen; Bayer; Day One Biopharmaceuticals; Loxo; Merck KGaA
Patents, Royalties, Other Intellectual Property - US patent 62/318,041 issued to Loxo Oncology. (Inst); US patent 63/251,445 issued to Day One Biopharmaceuticals, Inc. (Inst)
 
Olaf Witt
No Relationships to Disclose
 
Lindsay Baker Kilburn
Employment - Kaiser Permanente (I)
Consulting or Advisory Role - Roche/Genentech
Research Funding - Epizyme (Inst); Novartis (Inst); Regeneron (Inst)
 
Jordan R. Hansford
No Relationships to Disclose